Use of Multimodality Neoadjuvant Therapy for Esophageal Cancer in the United States: Assessment of 987 Hospitals

Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial

(2011) Marc Ychou et al.   JOURNAL OF CLINICAL ONCOLOGY

Esophageal cancer: Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2010) M. Stahl et al.   ANNALS OF ONCOLOGY

Systematic review of the benefits and risks of neoadjuvant chemoradiation for oesophageal cancer

(2010) E. F. W. Courrech Staal et al.   BRITISH JOURNAL OF SURGERY

Cancer Statistics, 2009

(2009) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Trends in the management of esophageal carcinoma based on provider volume: treatment practices of 618 esophageal surgeons

(2009) C. K. Enestvedt et al.   DISEASES OF THE ESOPHAGUS

Long-Term Results of a Randomized Trial of Surgery With or Without Preoperative Chemotherapy in Esophageal Cancer

(2009) William H. Allum et al.   JOURNAL OF CLINICAL ONCOLOGY

Neoadjuvant chemoradiotherapy for resectable esophagealcarcinoma: A meta-analysis

(2009) Hai-Lin Jin et al.   WORLD JOURNAL OF GASTROENTEROLOGY

The National Cancer Data Base: A Powerful Initiative to Improve Cancer Care in the United States

(2008) Karl Y. Bilimoria et al.   ANNALS OF SURGICAL ONCOLOGY

Worldwide esophageal cancer collaboration

(2008) T. W. Rice et al.   DISEASES OF THE ESOPHAGUS

Phase III Trial of Trimodality Therapy With Cisplatin, Fluorouracil, Radiotherapy, and Surgery Compared With Surgery Alone for Esophageal Cancer: CALGB 9781

(2008) Joel Tepper et al.   JOURNAL OF CLINICAL ONCOLOGY